0001104659-26-057113
SEC filingIntensified R&D investment in barzolvolimab drove deeper Q1 losses and elevated cash burn, as revenue fell sharply while clinical development accelerated per management discussion.
Management's outlook in Item 2 underscores uncertainties: cash burn is projected to rise with barzolvolimab's expanded development, while expenditures face risks from development timelines or lack of partnerships. Inability to timely complete projects or secure collaborations could further elevate capital needs and pressure liquidity. The investment policy prioritizes principal preservation and liquidity, positioning the company to navigate these dynamics while pursuing barzolvolimab's potential amid biotech norms of high upfront investment for long-term value creation.